New Risk • Jun 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Share price has been highly volatile over the past 3 months (21% average weekly change). Market cap is less than US$10m (€4.96m market cap, or US$5.75m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding). Announcement • May 26
2cureX AB (publ), Annual General Meeting, Jun 25, 2026 2cureX AB (publ), Annual General Meeting, Jun 25, 2026, at 10:00 W. Europe Standard Time. Location: premises of forvis mazars, nordenskioldsgatan 11a, se-211 19 malmo, sweden, malmo Sweden Board Change • May 20
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Co-Founder & Chairman Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Announcement • Aug 22
2cureX AB (publ) (OM:2CUREX) acquired Cellphenomics GmbH for €44 million. 2cureX AB (publ) (OM:2CUREX) acquired Cellphenomics GmbH for €44 million in the first half of 2025. A cash consideration of €44 million will be paid by 2cureX AB (publ). As part of consideration, €44 million is paid towards common equity of Cellphenomics GmbH.
2cureX AB (publ) (OM:2CUREX) completed the acquisition of Cellphenomics GmbH for €44 million in the first half of 2025. Announcement • Apr 14
2cureX AB (publ), Annual General Meeting, Jun 26, 2025 2cureX AB (publ), Annual General Meeting, Jun 26, 2025, at 15:00 W. Europe Standard Time. Location: at the offices of forvis mazars, located at nordenskioldsgatan 11a, 211 19, malmo Sweden Announcement • Feb 27
2cureX AB (publ) to Report Second Half, 2025 Results on Feb 26, 2026 2cureX AB (publ) announced that they will report second half, 2025 results on Feb 26, 2026 Announcement • Sep 25
2cureX AB (publ) Approves the Election of New Board Members At the Extraordinary General Meeting of 2cureX AB (publ) on 24 September 2024, it was decided to elect Nathaniel Hutley and Dan Honeywell as new board members. The Board of Directors hereafter consists of Tonny Bülow-Nielsen, Grith Hagel, Ole Thastrup, Nathaniel Hutley and Dan Honeywell. Nathaniel Hutley and Dan Honeywell will be strong additions to the Board of Directors with international expertise in building global companies focussing on direct to customer business models. Reported Earnings • Aug 23
First half 2024 earnings released: kr0.54 loss per share (vs kr0.89 loss in 1H 2023) First half 2024 results: kr0.54 loss per share (improved from kr0.89 loss in 1H 2023). Net loss: kr9.56m (loss narrowed 39% from 1H 2023). Announcement • Jun 19
2cureX AB (publ) Announces CEO Changes 2cureX AB (publ) announced the appointment of its Founder, Ole Thastrup, as the new CEO. Additionally, the company extend its gratitude to its CFO Kenneth G. Johansen for taking the responsibility as Acting CEO in an interim period. Announcement • May 09
2cureX AB (publ) to Report Q4, 2024 Results on Feb 20, 2025 2cureX AB (publ) announced that they will report Q4, 2024 results on Feb 20, 2025 Board Change • Mar 05
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Co-Founder & Vice Chairman Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Announcement • Mar 01
2curex AB (publ) Elects Grith Hagel as a New Board Member 2cureX AB (publ) decided to elect Grith Hagel as a new board member. This election a part of a strategic initiative as 2cureX refines its strategy to facilitate the implementation of IndiTreat® testing across individual hospitals. Such a move towards decentralization necessitates an enhancement of the company's expertise in technical and regulatory areas. Grith Hagel is poised to significantly contribute to the integration and adoption of the IndiTreat® platform within cancer hospitals due to her background and expertise. The Board of Directors hereafter consists of Tonny Bülow-Nielsen, Grith Hagel and Ole Thastrup. Reported Earnings • Feb 25
Full year 2023 earnings released: kr1.75 loss per share (vs kr1.69 loss in FY 2022) Full year 2023 results: kr1.75 loss per share (further deteriorated from kr1.69 loss in FY 2022). Net loss: kr30.8m (loss widened 3.5% from FY 2022). Announcement • Jan 10
2cureX AB (publ), Annual General Meeting, May 23, 2024 2cureX AB (publ), Annual General Meeting, May 23, 2024. Announcement • Dec 06
2cureX AB (publ) Receives Ethical Approval for HIPEC Clinical Trial 2cureX AB (publ) announced the approval from the Ethical Committee at Fundacion Jimenez Diaz in Madrid to start a clinical trial using IndiTreat? in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in metastatic colorectal cancer patients. An IndiTreat®? test for this innovative treatment approach will bring additional value to 2cureX's ZENITH project for enabling in-house IndiTreat®? testing at hospital sites. Understanding HIPEC. HIPEC (short for hyperthermic intraperitoneal chemotherapy) is an advanced treatment procedure designed to address cancer metastases in the abdomen. HIPEC procedures comprise the rinsing of the abdominal cavity with heated chemotherapy solutions after surgery. This targeted approach allows for higher local concentrations of chemotherapy with the intention to maximize effectiveness while minimizing systemic side effects. This treatment is primarily offered to patients with cancers originating in the abdominal area, including colorectal cancer, gastric cancer, ovarian cancer, and mesothelioma. HIPEC approaches have shown promising results in increasing survival rates and improving the quality of life for patients with these challenging diagnoses. In this prospective trial, 2cureX's IndiTreat®? tests will identify the cytotoxic drug that has the most promising efficacy profile on an individual HIPEC patient's tumor. Reported Earnings • Nov 24
Third quarter 2023 earnings released: kr0.58 loss per share (vs kr0.47 loss in 3Q 2022) Third quarter 2023 results: kr0.58 loss per share (further deteriorated from kr0.47 loss in 3Q 2022). Net loss: kr10.2m (loss widened 22% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings. Announcement • Nov 15
2Curex AB (Publ) Appoints Tonni Bülow-Nielsen as Board Member and Chairman At the Extraordinary General Meeting of 2cureX AB (publ), 14 November 2023, the Extraordinary general meeting appointed Tonni Bülow-Nielsen as new board members. It was further decided to appoint Tonni Bülow-Nielsen as new Chairman. Announcement • Aug 31
2curex Launches Its First Two IndiTreat® Products Ce-Marked Under the New Ivd Regulation 2cureX announced the launch of two IVD products – IndiTreat® Specimen Collection Kit and IndiTreat® Shipping Container – that have become the first to be CE-marked under the new IVD-R by the company. The IndiTreat® Specimen Collection Kit is a replacement of the previous IndiTreat® Specimen Collection Set, while the IndiTreat® Shipping Container is a new device to ensure optimal conditions during transportation of patient samples from hospitals to the 2cureX testing facilities. The IndiTreat® test is performed on patient-derived 3D tumoroids that are biological replicas of the patient’s original tumor. To grow these 3D tumoroids, it is essential that the biopsy taken from the patient reaches the 2cureX testing facilities in optimal conditions. The IndiTreat® Specimen Collection Kit contains a specialized ready-to-use, single-use buffer capable of supporting the viability of specimen samples during transportation, as well as a temperature logging device to monitor the temperature that the specimen has been exposed to during shipment. The IndiTreat® Shipping Container is a specialized single-use shipping container capable of supporting specimens with optimal shipping conditions by providing stable temperatures within 2-8°C in the sealed payload compartment for at least 48 hours. The two new products will start to be commercialized immediately throughout the 20 countries where 2cureX has commercial operations, directly or through its network of distribution partnerships. Today’s news are in line with launching plans for 2023, and will not affect revenue expectations for the year. Reported Earnings • May 26
First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.45 loss in 1Q 2022) First quarter 2023 results: kr0.43 loss per share (improved from kr0.45 loss in 1Q 2022). Net loss: kr7.58m (loss narrowed 4.1% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 24
Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021) Full year 2022 results: kr1.69 loss per share (further deteriorated from kr1.15 loss in FY 2021). Net loss: kr29.8m (loss widened 57% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Reported Earnings • Feb 24
Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021) Full year 2022 results: kr1.69 loss per share (further deteriorated from kr1.15 loss in FY 2021). Net loss: kr29.8m (loss widened 57% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Announcement • Feb 11
2cureX AB (publ) Appoints Michel Klimkeit to Board of Director 2cureX AB (publ) at its extraordinary general meeting resolved the appointment of Michel Klimkeit as member of Board of Director. Reported Earnings • Nov 25
Third quarter 2022 earnings released: kr0.47 loss per share (vs kr0.31 loss in 3Q 2021) Third quarter 2022 results: kr0.47 loss per share (further deteriorated from kr0.31 loss in 3Q 2021). Net loss: kr8.35m (loss widened 54% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Board Change • Nov 16
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 3 experienced directors. 1 highly experienced director. Co-Founder, Deputy CEO, CSO & Director Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Jul 02
2cureX Announces Board Change 2cureX announced the appointment of Dr. Raphael Gruber as the new Medical Director. This is a critical position as clinical studies become an increasingly pivotal part of the 2cureX strategy. Dr. Gruber is joining 2cureX on July 1st, 2022, following Dr. Henrik Harling, who has decided to retire. After a highly successful career as a physician and, more recently, as Chief Medical Officer of 2cureX, Dr. Henrik Harling has decided to retire as of July 1st. Since 2019, Dr. Harling conducted tremendously valuable and committed work in completing the IndiTreat® portfolio. Dr. Gruber previously held the position of Medical Director at Exact Sciences in the DACH/NL region, where he successfully led the company´s medical strategies, including the introduction of their multigene assay into national reimbursement in Germany and the Netherlands. He previously spent ten years at Otsuka Pharmaceuticals Europe where he was in charge of their EU Medical Devices. He brings a rare combination of expertise in pharma and diagnostics, a deep understanding of the regulatory environment and a passion for developing clinical strategies to support the introduction of new medical technologies in oncology. Announcement • May 10
2cureX AB (publ) Presents Inditreat® Clinical Results At the Society for Functional Precision Medicine 2cureX is pioneering drug sensitivity testing for the individualized selection of cancer treatment. The company has been invited to present the IndiTreat® test and associated clinical data at a seminar organized by the Society for Precision Medicine (SFPM) on 11 May 2022, together with its clinical partner, University Hospital Vejle. 2cureX has led the development of functional drug sensitivity testing in oncology for the past 15 years. While this was previously viewed largely as a research tool, the medical community recognizes increasingly its significant role in individualizing the treatment of cancer patients. Board Change • Apr 27
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. 1 highly experienced director. Co-Founder, Deputy CEO, Member of Executive Board, CSO & Director Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Apr 22
Manuel Fernández Joins 2cureX as Director of Quality Assurance and Regulatory Affairs 2cureX announced a new member of its management team, Manuel Fernández. Manuel will use his many years of experience to lead the critical QA /RA function. Manuel Fernández has nearly 30 years' experience in Diagnostics and Medical Devices. His academic background is in mechatronics, robotics and automation engineering, as well as biomedical engineering. Throughout his career he has led QA /RA functions in several companies, becoming an expert in all relevant ISO norms. He has deep knowledge of the regulatory landscapes in Europe, US, China and Asia Pacific, and has worked with Notified Bodies and competent regulatory authorities in major countries. Announcement • Feb 24
2cureX AB (publ) Announces Management Changes 2cureX announced changes to its commercial organization. Jesper Floyd Kristiansen, currently VP Business Development Europe will take over additional responsibilities and change his title to VP Global Business Development. A new Director of Marketing Communications, Mark Gray, will join the company on March 1st. Pia van der Zee, currently VP Marketing, has accepted a position outside of 2cureX and will leave the company mid-March. All activities related to distributor support will become part of the Business Development department, led by Jesper Floyd Kristiansen, whose title going forward will be VP Global Business Development. With this change the company seeks to group all distributor-related activities under one head, to strengthen alignment and continuity. For the Marketing Communications activities, a new Director, Marketing Communications will join 2cureX on March 1st. Mark Gray is a communications professional with a long experience in the In Vitro Diagnostics industry, where he has developed his career in leading companies like Sysmex Europe. Pia van der Zee who was holding the role of VP Marketing, has decided to pursue an opportunity outside of 2cureX and will leave the company in mid-March. Pia has played an important role leading marketing projects in the last months, and the company wants to recognize her contribution and wish her all kinds of success in her new position. Announcement • Dec 15
2cureX Launches IndiTreat mCRC Start Test to Guide First Line Treatment 2cureX announced the launch of the IndiTreat mCRC Start test, to guide first line drug therapy in patients with metastatic colorectal cancer (mCRC). The test is the second in the mCRC portfolio following IndiTreat mCRC Extend, for third line treatment. The announcement is in line with previous statements by 2cureX about their product portfolio expansion (Q2 and Third Quarter 2021 Reports). The first IndiTreat test is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer facing their third line of therapy. Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers. Board Change • Sep 20
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. Co-Founder, Deputy CEO, Member of Executive Board, CSO & Director Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Sep 13
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. Co-Founder, Deputy CEO, Member of Executive Board, CSO & Director Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Sep 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. Co-Founder, Deputy CEO, Member of Executive Board, CSO & Director Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Aug 21
2cureX Announces New Development of the IndiTreat Technology Allows Prediction of Response to Anti-Angiogenic Drugs in Colorectal Cancer 2cureX announced that it has been able to predict response to anti-angiogenic drugs with a modified version of its IndiTreat technology. The development could be the basis for a new product addressing this drug class. The results have been published together with Rigshospitalet, Bispebjerg Hospital, University of Copenhagen and University of Bristol. Solid tumors require an increased consumption of oxygen and nutrients to grow and spread. In order to get this extra inflow, tumors create new blood vessels and hijack existing ones, a process called angiogenesis. It is proven that, without angiogenesis, a tumor can't grow beyond 2mm and can't metastasize. Inhibiting angiogenesis is therefore a powerful therapeutic strategy, and several drugs are available for this purpose, collectively called anti-angiogenics. Currently, there are no molecular biomarkers available to predict if a specific patient tumor will respond to anti-angiogenics, therefore, the drug is prescribed to patients who will eventually not benefit from it. 2cureX has developed a specific version of its IndiTreat technology that measures the angiogenic capacity of a tumor and predicts its response to treatment with anti-angiogenics. The method and the results have been published in the article "The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids". IndiTreat is a technology to generate in vitro hundreds of 3D replicas, called tumoroids, derived from a patient's tumor. These tumoroids are then exposed to different drugs in order to assess its efficacy, allowing the treating physician to optimize the treatment regime for that specific patient. Announcement • May 21
2Curex AB (Publ) Clinical Partner, University Hospital Vejle, Presents Positive Results of Thnditreat®-Guided Clinicaical Trial in Third Line Metastatic Colorectal Cancer At the Asco 2021 Annual Meeting 2cureX AB (publ) announced that the outcome of the clinical trial (NC3251612, TICC) is published by ASCO prior to its Annual Meeting in June 2021. The primary endpoint of the trial was met.
The patients enrolled in the trial suffered from end stage metastatic colorectal cancer and had IndiTreat®-guided third line treatment selected from a panel of 15 drug regimen. They comprised standard cytostatics and other cancer drugs with proven effect in clinical trials. The primary endpoint was Progression Free Survival (PFS) after 8 weeks of treatment. PFS of placebo arms in randomized last-line trials is 20% and the success criterion of the present trial was set at 40%. 90 patients were enrolled in the trial, 82 underwent biopsy from liver metastases of which 44 (54%) succeeded in producing microtumors which could be IndiTreat® drug screened with identification of at least one possible treatment. Thirty-four patients were treated in accordance with
the test result and 17 (50%) obtained PFS after 8 weeks. The median PFS of patients undergoing IndiTreat®-guided third line treatment was 81 days and median overall survival (OS) was 189 days. Announcement • Mar 03
2cureX AB (publ) Announces Clinical Trial of Inditreat®-Guided Treatment of Metastatic Colorectal Cancer 2cureX announced that its prospective interventional clinical trial investigating the benefit of IndiTreat®-guided treatment achieved its
primary endpoint by improving Progression Free Survival (PFS) after eight weeks of treatment. Full data has been submitted to the American Society of
Clinical Oncology (ASCO) 2021 Annual Meeting. Colorectal cancer is the 2nd most common cancer in women and the 3rd most common in men. A single-center, phase II trial included patients with metastatic colorectal cancer previously exposed to all standard therapies. A panel of off-label drugs were tested in the IndiTreat® test, and the most effective treatment was provided to the patient. The primary endpoint of the trial was the fraction of patients with Progression-Free-Survival (PFS) after two months of IndiTreat-guided treatment. Announcement • Feb 26
2cureX AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022 2cureX AB (publ) announced that they will report fiscal year 2021 results on Feb 24, 2022 Is New 90 Day High Low • Feb 07
New 90-day high: €2.19 The company is up 49% from its price of €1.47 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 23% over the same period. Announcement • Feb 05
2cureX AB's IndiTreat® Selected to Prestigious Multinational Ovarian Cancer Project 2cureX announced that the DECIDER project that aims to develop novel diagnostic tools and effective drug combinations to treat ovarian cancer patients has been awarded a prestigious grant from the EU. 2cureX will provide functional precision testing within a prestigious multinational Ovarian Cancer project, DECIDER, which has been granted 15 MEUR from the EU. The invitation to participate is an endorsement of IndiTreat®, and in line with 2cureX's belief that every cancer patient should be treated individually. Executive Departure • Feb 03
Chief Financial Officer has left the company On the 1st of February, Carit Andersen's tenure as Chief Financial Officer ended after 2.0 years in the role. As of September 2020, Carit personally held only 11.72k shares (€18k worth at the time). A total of 2 executives have left over the last 12 months. Announcement • Jan 29
2cureX Appoints Kenneth Graabek Johansen as New CFO, Effective 1 February 2021 2cureX announced that Kenneth Graabek Johansen has been appointed new CFO and will start on 1 February 2021. Kenneth has a strong track record in business administration at executive level in the biomedical area. With positions such as COO and Co-founder of JADBio, Kenneth will add many years of experience in strengthening the business and financial development dimension, which is key to positioning 2cureX as a world leader in Functional Precision Medicine. Announcement • Jan 22
2cureX Announces Last Patient Treated in the World's First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment 2cureX's clinical partner University Hospital Vejle has treated the last patient in the TICC1 clinical trial (Clinicaltrials.gov no. NCT03251612) in metastatic colorectal cancer. 2cureX and University Hospital Vejle are in the process of analyzing the clinical data from the trial with expected publication of the results in first quarter of 2021. Is New 90 Day High Low • Jan 15
New 90-day high: €1.83 The company is up 18% from its price of €1.55 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. Announcement • Jan 06
2cureX Announces Management Changes 2cureX announced that Fernando Andreu has been appointed new CEO and will start latest on 1 April 2021. Ole Thastrup the present CEO and Founder of 2cureX will continue as CSO, being responsible for 2cureX's clinical and scientific activities. Fernando Andreu is leaving positions as CEO of Indivumed Inc. (US) and CBO of Indivumed Group (DE) to join 2cureX. Fernando will provide an important strengthening of the commercial and business development dimension of the company, which is needed to position 2cureX as a world leader in Functional Precision Medicine. Is New 90 Day High Low • Dec 31
New 90-day high: €1.66 The company is up 3.0% from its price of €1.61 on 02 October 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period. Is New 90 Day High Low • Oct 21
New 90-day low: €1.50 The company is down 13% from its price of €1.72 on 23 July 2020. The German market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 1.0% over the same period. Announcement • Oct 04
2cureX Announces Last Patient Successfully Enrolled in the Worlds First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment 2cureX s clinical partner University Hospital Vejle, enrolled the la patient in the clinical valididation study TICC1. In this interventional study, IndiTreat® test results guide the drug treatment of patients with metastatic colorectal cancer who have exhausted guideline-based treatment options. The TICC1 clinical trial (Clinicaltrials.gov no. NCT03251612) was launched end 2017 with the purpose of evaluating IndiTreats ability to successfully guide the drug therapy of end-stage metastatic colorectal cancer patients. As planned in the trial protocol, 45 patients have been enrolled and treated in accordance with the IndiTreat® results. This trial is the worlds first interventional trial where patient treatment is guided by 3D microtumor technology. The concept of testing the effects of drugs directly on the patients tumor cells in the laboratory is very appealing to both oncologists and patients. Back in 2017 it suggested using the IndiTreat® test to screen a panel of standard and off-label drugs to identify treatments to which the patient was sensitive and exclude drugs the patient was resistant to. It is a great pleasure that it have now completed the inclusion of patients for this trial. The last patient will now be treated according to the test result, and the outcome will be evaluated after eight weeks. The results of the study will be published when all data have been analyzed, says Lars Henrik Jensen, Principal Investigator at University Hospital Vejle. Inditreat will empower oncologist to choose the best possible treatment At the moment, there is no evidence-based treatment recommendation for patients when guideline recommendations are exhausted. The ambition of the novel IndiTreat® test is to empower oncologists to choose the best possible treatment even for severely sick patients such as those included in the TICC1 trial. Is New 90 Day High Low • Sep 28
New 90-day low: €1.62 The company is down 4.0% from its price of €1.69 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 1.0% over the same period. Announcement • Sep 15
2cureX launches world's first CE-marked microtumor test service 2cureX announced that IndiTreat® is now available for clinics throughout the EU. Through the fulfillment of CE marking, EU registered clinics can use the IndiTreat Test to match an individual cancer patient to the most effective cancer treatment. 
